Farnesyl transferase inhibitors

Journal of Lipid Research

Volumn 47, Issue 1, 2006, Pages 15-31

  Basso, Andrea D ^a   Kirschmeier, Paul ^a   Bishop, W Robert ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

BMS 214662; CENP; HDJ; Iamin; Ionafarnib; L 778123; Ras; Rheb; RhoB; Tipifarnib

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; L 778123; LONAFARNIB; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; RAS PROTEIN; RHOB GUANINE NUCLEOTIDE BINDING PROTEIN; TIPIFARNIB; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; FARNESYL TRANS TRANSFERASE;

ANCHORAGE INDEPENDENT GROWTH; CARBOXY TERMINAL SEQUENCE; DRUG STRUCTURE; ENZYME SUBSTRATE; GENE OVEREXPRESSION; HUMAN; PRENYLATION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; LIPID METABOLISM; METABOLISM; NEOPLASM; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; HUMANS; LIPID METABOLISM; NEOPLASMS; PROTEIN ISOPRENYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RAS PROTEINS;

EID: 30844467746     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.R500012-JLR200     Document Type: Review

References (220)

1. Reiss, Y., S. J. Stradley, L. M. Gierasch, M. S. Brown, and J. L. Goldstein. 1991. Sequence requirement for peptide recognition by rat brain p21ras protein farnesyltransferase. Proc. Natl. Acad. Sci. USA. 88: 732-736.
2. Yokoyama, K., G. W. Goodwin, F. Ghomashchi, J. A. Glomset, and M. H. Gelb. 1991. A protein geranylgeranyltransferase from bovine brain: implications for protein prenylation specificity. Proc. Natl. Acad. Sci. USA. 88: 5302-5306.
3. Casey, P. J., P. A. Solski, C. J. Der, and J. E. Buss. 1989. p21ras is modified by a farnesyl isoprenoid. Proc. Natl. Acad. Sci. USA. 86: 8323-8327.
4. Wolda, S. L., and J. A. Glomset. 1998. Evidence for modification of laminBby a product of mevalonic acid. J. Biol. Chem. 263: 5997-6000.
5. Caplan, A. J., J. Tsai, P. J. Casey, and M. G. Douglas. 1992. Farnesylation of YDJ1p is required for function at elevated growth temperatures in Saccharomyces cerevisiae. J. Biol. Chem. 267: 18890-18895.
6. Wang, J., C. E. Kirby, and R. Herbst. 2002. The tyrosine phosphatase PRL-1 localizes to the endoplasmic reticulum and the mitotic spindle and is required for normal mitosis. J. Biol. Chem. 277: 46659-46668.
7. Adamson, P., C. J. Marshall, A. Hall, and P. A. Tilbrook. 1992. Post-translational modifications of p21rho proteins. J. Biol. Chem. 267: 20033-20038.
8. Clark, G. J., M. S. Kinch, K. Rogers-Graham, S. M. Sebti, A. D. Hamilton, and C. J. Der. 1997. The Ras-related protein Rheb is farnesylated and antagonizes Ras signaling and transformation. J. Biol. Chem. 272: 10608-10615.
9. Ashar, H. R., L. James, K. Gray, D. Carr, S. Black, L. Armstrong, W. R. Bishop, and P. Kirschmeier. 2000. Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. J. Biol. Chem. 275: 30451-30457.
10. Shen, F., and M. Seabra. 1996. Mechanism of digeranylgeranylation of Rab proteins. Formation of a complex between monogeranylgeranyl-Rab and Rab escort protein. J. Biol. Chem. 271: 3692-3698.
11. Seabra, M. C., Y. Reiss, P. J. Casey, M. S. Brown, and J. L. Goldstein. 1991. Protein farnesyltransferase and geranylgeranyltransferase share a common alpha subunit. Cell. 65: 429-434.
12. 2+-farnesyltransferase indicates metal coordination of the substrate thiolate. J. Biol. Chem. 272: 20-23.
13. Furfine, E. S., J. J. Leban, A. Landavazo, J. F. Moomaw, and P. J. Casey. 1995. Protein farnesyltransferase: kinetics of farnesyl pyrophosphate binding and product release. Biochemistry. 34: 6857-6862.
14. Reid, T. S., S. B. Long, and L. S. Beese. 2004. Crystallographic analysis reveals that anticancer clinical candidate L-778,123 inhibits protein farnesyltransferase and geranylgeranyltransferase-I by different binding modes. Biochemistry. 43: 9000-9008.
15. Reid, T. S., K. L. Terry, P. J. Casey, and L. S. Beese. 2004. Crystallographic analysis of CaaX prenyltransferases complexed with substrates defines rules of protein substrate selectivity. J. Mol. Biol. 343: 417-433.
16. Long, S. B., P. J. Hancock, A. M. Kral, H. W. Hellinga, and L. S. Beese. 2001. The crystal structure of human protein farnesyltransferase reveals the basis for inhibition by CaaX tetrapeptides and their mimetics. Proc. Natl. Acad. Sci. USA. 98: 12948-12953.
17. Strickland, C. L., W. T. Windsor, R. Syto, L. Wang, R. Bond, Z. Wu, J. Schwartz, H. V. Le, L. S. Beese, and P. C. Weber. 1998. Crystal structure of farnesyl protein transferase complexed with a CaaX peptide and farnesyl diphosphate analogue. Biochemistry. 37: 16601-16611.
18. Long, S. B., P. J. Casey, and L. S. Beese. 1998. Cocrystal structure of protein farnesyltransferase complexed with a farnesyl diphosphate substrate. Biochemistry. 37: 9612-9618.
19. Bos, J. L. 1989. ras oncogenes in human cancer: a review. Cancer Res. 49: 4682-4689.
20. Reiss, Y., J. L. Goldstein, M. C. Seabra, P. J. Casey, and M. S. Brown. 1990. Inhibition of purified p21ras farnesyl:protein transferase by Cys-AAX tetrapeptides. Cell. 62: 81-88.
21. Brown, M. S., J. L. Goldstein, K. J. Paris, J. P. Burnier, and J. C. Marsters, Jr. 1992. Tetrapeptide inhibitors of protein farnesyltransferase: amino-terminal substitution in phenylalanine-containing tetrapeptides restores farnesylation. Proc. Natl. Acad. Sci. USA. 89: 8313-8316.
22. Goldstein, J. L., M. S. Brown, S. J. Stradley, Y. Reiss, and L. M. Gierasch. 1991. Nonfarnesylated tetrapeptide inhibitors of protein farnesyltransferase. J. Biol. Chem. 266: 15575-15578.
23. James, G. L., J. L. Goldstein, M. S. Brown, T. E. Rawson, T. C. Somers, R. S. McDowell, C. W. Crowley, B. K. Lucas, A. D. Levinson, and J. C. Marsters, Jr. 1993. Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells. Science. 260: 1937-1942.
24. Qian, Y., M. A. Blaskovich, M. Saleem, C. M. Seong, S. P. Wathen, A. D. Hamilton, and S. M. Sebti. 1994. Design and structural requirements of potent peptidomimetic inhibitors of p21ras farnesyltransferase. J. Biol. Chem. 269: 12410-12413.
25. Vogt, A., Y. Qian, M. A. Blaskovich, R. D. Fossum, A. D. Hamilton, and S. M. Sebti. 1995. A non-peptide mimetic of Ras-CAAX: selective inhibition of farnesyltransferase and Ras processing. J. Biol. Chem. 270: 660-664.
26. Nigam, M., C. M. Seong, Y. Qian, A. D. Hamilton, and S. M. Sebti. 1993. Potent inhibition of human tumor p21ras farnesyltransferase by A1A2-lacking p21ras CA1A2X peptidomimetics. J. Biol. Chem. 268: 20695-20698.
27. Hara, M., K. Akasaka, S. Akinaga, M. Okabe, H. Nakano, R. Gomez, D. Wood, M. Uh, and F. Tamanoi. 1993. Identification of Ras farnesyltransferase inhibitors by microbial screening. Proc. Natl. Acad. Sci. USA. 90: 2281-2285.
28. Scholten, J. D., K. K. Zimmerman, M. G. Oxender, D. Leonard, J. Sebolt-Leopold, R. Gowan, and D. J. Hupe. 1997. Synergy between anions and farnesyldiphosphate competitive inhibitors of farnesyl: protein transferase. J. Biol. Chem. 272: 18077-18081.
29. Gibbs, J. B., D. L. Pompliano, S. D. Mosser, E. Rands, R. B. Lingham, S. B. Singh, E. M. Scolnick, N. E. Kohl, and A. Oliff. 1993. Selective inhibition of farnesyl-protein transferase blocks ras processing in vivo. J. Biol. Chem. 268: 7617-7620.
30. Bishop, W. R., R. Bond, J. Petrin, L. Wang, R. Patton, R. Doll, G. Njoroge, J. Catino, J. Schwartz, W. Windsor, et al. 1995. Novel tricyclic inhibitors of farnesyl protein transferase. Biochemical characterization and inhibition of Ras modification in transfected Cos cells. J. Biol. Chem. 270: 30611-30618.
31. Njoroge, F. G., A. G. Taveras, J. Kelly, S. Remiszewski, A. K. Mallams, R. Wolin, A. Afonso, A. B. Cooper, D. F. Rane, Y. T. Liu, et al. 1998. (1)-4-[2-[4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5, 6]cyclohepta[1,2-b]- pyridin-11(R)-yl)-1-piperidinyl]-2-oxo-ethyl]-1-piperidinecarboxamide (SCH-66336): a very potent farnesyl protein transferase inhibitor as a novel antitumor agent. J. Med. Chem. 41: 4890-4902.
32. End, D. W., G. Smets, A. V. Todd, T. L. Applegate, C. J. Fuery, P. Angibaud, M. Venet, G. Sanz, H. Poignet, S. Skrzat, et al. 2001. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res. 61: 131-137.
33. Hunt, J. T., C. Z. Ding, R. Batorsky, M. Bednarz, R. Bhide, Y. Cho, S. Chong, S. Chao, J. Gullo-Brown, P. Guo, et al. 2000. Discovery of (R)-7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl) -4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine (BMS-214662), a farnesyltransferase inhibitor with potent preclinical antitumor activity. J. Med. Chem. 43: 3587-3595.
34. Lackner, M. R., R. M. Kindt, P. M. Carroll, K. Brown, M. R. Cancilla, C. Chen, H. de Silva, Y. Franke, B. Guan, T. Heuer, et al. 2005. Chemical genetics identifies Rab geranylgeranyl transferase as an apoptotic target of farnesyl transferase inhibitors. Cancer Cell. 7: 325-336.
35. Buser, C. A., C. J. Dinsmore, C. Fernandes, I. Greenberg, K. Hamilton, S. D. Mosser, E. S. Walsh, T. M. Williams, and K. S. Koblan. 2001. High-performance liquid chromatography/mass spectrometry characterization of Ki4B-Ras in PSN-1 cells treated with the prenyltransferase inhibitor L-778,123. Anal. Biochem. 290: 126-137.
36. Mulcahy, L. S., M. R. Smith, and D. W. Stacey. 1985. Requirement for ras proto-oncogene function during serum-stimulated growth of NIH 3T3 cells. Nature. 313: 241-243.
37. Stacey, D. W., M. Roudebush, R. Day, S. D. Mosser, J. B. Gibbs, and L. A. Feig. 1991. Dominant inhibitory Ras mutants demonstrate the requirement for Ras activity in the action of tyrosine kinase oncogenes. Oncogene. 6: 2297-2304.
38. Shirasawa, S., M. Furuse, N. Yokoyama, and T. Sasazuki. 1993. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science. 260: 85-88.
39. Egan, S. E., B. W. Giddings, M. W. Brooks, L. Buday, A. M. Sizeland, and R. A. Weinberg. 1993. Association of Sos Ras exchange protein with Grb2 is implicated in tyrosine kinase signal transduction and transformation. Nature. 363: 45-51.
40. Lowenstein, E. J., R. J. Daly, A. G. Batzer, W. Li, B. Margolis, R. Lammers, A. Ullrich, E. Y. Skolnik, D. Bar-Sagi, and J. Schlessinger. 1992. The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling. Cell. 70: 431-442.
41. Stokoe, D., S. G. Macdonald, K. Cadwallader, M. Symons, and J. F. Hancock. 1994. Activation of Raf as a result of recruitment to the plasma membrane. Science. 264: 1463-1467.
42. Leevers, S. J., H. F. Paterson, and C. J. Marshall. 1994. Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane. Nature. 369: 411-414.
43. Crews, C. M., and R. L. Erikson. 1992. Purification of a murine protein-tyrosine/threonine kinase that phosphorylates and activates the Erk-1 gene product: relationship to the fission yeast byr1 gene product. Proc. Natl. Acad. Sci. USA. 89: 8205-8209.
44. Schaap, D., J. van der Wal, L. R. Howe, C. J. Marshall, and W. J. van Blitterswijk. 1993. A dominant-negative mutant of raf blocks mitogen-activated protein kinase activation by growth factors and oncogenic p21ras. J. Biol. Chem. 268: 20232-20236.
45. Marais, R., J. Wynne, and R. Treisman. 1993. The SRF accessory protein Elk-1 contains a growth factor-regulated transcriptional activation domain. Cell. 73: 381-393.
46. Urano, T., R. Emkey, and L. A. Feig. 1996. Ral-GTPases mediate a distinct downstream signaling pathway from Ras that facilitates cellular transformation. EMBO J. 15: 810-816.
47. Rodriguez-Viciana, P., P. H. Warne, B. Vanhaesebroeck, M. D. Waterfield, and J. Downward. 1996. Activation of phosphoinositide 3-kinase by interaction with Ras and by point mutation. EMBO J. 15: 2442-2451.
48. Gutierrez, L., A. I. Magee, C. J. Marshall, and J. F. Hancock. 1989. Post-translational processing of p21ras is two-step and involves carboxyl-methylation and carboxy-terminal proteolysis. EMBO J. 8: 1093-1098.
49. Swarthout, J. T., S. Lobo, L. Farh, M. R. Croke, W. K. Greentree, R. J. Deschenes, and M. E. Linder. 2005. DHHC9 and GCP16 constitute a human protein fatty acyltransferase with specificity for H-and N-Ras. J. Biol. Chem. 280: 31141-31148.
50. Silvius, J. R., and F. l'Heureux. 1994. Fluorimetric evaluation of the affinities of isoprenylated peptides for lipid bilayers. Biochemistry. 33: 3014-3022.
51. Hancock, J. F., K. Cadwallader, and C. J. Marshall. 1991. Methylation and proteolysis are essential for efficient membrane binding of prenylated p21K-ras(B). EMBO J. 10: 641-646.
52. Bergo, M. O., P. Ambroziak, C. Gregory, A. George, J. C. Otto, E. Kim, H. Nagase, P. J. Casey, A. Balmain, and S. G. Young. 2002. Absence of the CAAX endoprotease Rce1: effects on cell growth and transformation. Mol. Cell. Biol. 22: 171-181.
53. Bergo, M. O., G. K. Leung, P. Ambroziak, J. C. Otto, P. J. Casey, and S. G. Young. 2000. Targeted inactivation of the isoprenylcysteine carboxyl methyltransferase gene causes mislocalization of K-Ras in mammalian cells. J. Biol. Chem. 275: 17605-17610.
54. Magee, T., and M. C. Seabra. 2005. Fatty acylation and prenylation of proteins: what's hot in fat. Curr. Opin. Cell Biol. 17: 190-196.
55. James, G. L., J. L. Goldstein, and M. S. Brown. 1995. Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro. J. Biol. Chem. 270: 6221-6226.
56. Zhang, F. L., P. Kirschmeier, D. Carr, L. James, R. W. Bond, L. Wang, R. Patton, W. T. Windsor, R. Syto, R. Zhang, et al. 1997. Characterization of Ha-ras, N-ras, Ki-Ras4A, and Ki-Ras4B as in vitro substrates for farnesyl protein transferase and geranylgeranyl protein transferase type I. J. Biol. Chem. 272: 10232-10239.
57. Kohl, N. E., S. D. Mosser, S. J. deSolms, E. A. Giuliani, D. L. Pompliano, S. L. Graham, R. L. Smith, E. M. Scolnick, A. Oliff, and J. B. Gibbs. 1993. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science. 260: 1934-1937.
58. Kohl, N. E., C. A. Omer, M. W. Conner, N. J. Anthony, J. P. Davide, S. J. deSolms, E. A. Giuliani, R. P. Gomez, S. L. Graham, and K. Hamilton. 1995. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat. Med. 1: 792-797.
59. Whyte, D. B., P. Kirschmeier, T. N. Hockenberry, I. Nunez-Oliva, L. James, J. J. Catino, W. R. Bishop, and J. K. Pai. 1997. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J. Biol. Chem. 272: 14459-14464.
60. Law, B. K., P. Norgaard, L. Gnudi, B. B. Kahn, H. S. Poulson, and H. L. Moses. 1999. Inhibition of DNA synthesis by a farnesyltransferase inhibitor involves inhibition of the p70(s6k) pathway. J. Biol. Chem. 274: 4743-4748.
61. Moasser, M. M., and N. Rosen. 2002. The use of molecular markers in farnesyltransferase inhibitor (FTI) therapy of breast cancer. Breast Cancer Res. Treat. 73: 135-144.
62. Omer, C. A., Z. Chen, R. E. Diehl, M. W. Conner, H. Y. Chen, M. E. Trumbauer, S. Gopal-Truter, G. Seeburger, H. Bhimnathwala, M. T. Abrams, et al. 2000. Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor. Cancer Res. 60: 2680-2688.
63. Mangues, R., T. Corral, N. E. Kohl, W. F. Symmans, S. Lu, M. Malumbres, J. B. Gibbs, A. Oliff, and A. Pellicer. 1998. Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice. Cancer Res. 58: 1253-1259.
64. Cox, A. D., A. M. Garcia, J. K. Westwick, J. J. Kowalczyk, M. D. Lewis, D. A. Brenner, and C. J. Der. 1994. The CAAX peptidomimetic compound B581 specifically blocks farnesylated, but not geranylgeranylated or myristylated, oncogenic ras signaling and transformation. J. Biol. Chem. 269: 19203-19206.
65. Lebowitz, P. F., P. J. Casey, G. C. Prendergast, and J. A. Thissen. 1997. Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB. J. Biol. Chem. 272: 15591-15594.
66. Lebowitz, P. F., J. P. Davide, and G. C. Prendergast. 1995. Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity. Mol. Cell. Biol. 15: 6613-6622.
67. Shih, T. Y., M. O. Weeks, P. Gruss, R. Dhar, S. Oroszlan, and E. M. Scolnick. 1982. Identification of a precursor in the biosynthesis of the p21 transforming protein of harvey murine sarcoma virus. J. Virol. 42: 253-261.
68. Du, W., P. F. Lebowitz, and G. C. Prendergast. 1999. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB. Mol. Cell. Biol. 19: 1831-1840.
69. Mazieres, J., V. Tillement, C. Allal, C. Clanet, L. Bobin, Z. Chen, S. M. Sebti, G. Favre, and A. Pradines. 2005. Geranylgeranylated, but not farnesylated, RhoB suppresses Ras transformation of NIH-3T3 cells. Exp. Cell Res. 304: 354-364.
70. Kamasani, U., M. Huang, J. B. Duhadaway, E. V. Prochownik, P. S. Donover, and G. C. Prendergast. 2004. Cyclin B1 is a critical target of RhoB in the cell suicide program triggered by farnesyl transferase inhibition. Cancer Res. 64: 8389-8396.
71. Chen, Z., J. Sun, A. Pradines, G. Favre, J. Adnane, and S. M. Sebti. 2000. Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice. J. Biol. Chem. 275: 17974-17978.
72. Wang, D. A., and S. M. Sebti. 2005. Palmitoylated cysteine 192 is required for RhoB tumor-suppressive and apoptotic activities. J. Biol. Chem. 280: 19243-19249.
73. Vogt, A., J. Sun, Y. Qian, A. D. Hamilton, and S. M. Sebti. 1997. The geranylgeranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in G0/G1 and induces p21(WAF1/CIP1/SDI1) in a p53-independent manner. J. Biol. Chem. 272: 27224-27229.
74. Liu, A., W. Du, J. P. Liu, T. M. Jessell, and G. C. Prendergast. 2000. RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors. Mol. Cell. Biol. 20: 6105-6113.
75. Yamagata, K., L. K. Sanders, W. E. Kaufmann, W. Yee, C. A. Barnes, D. Nathans, and P. F. Worley. 1994. rheb, a growth factor- and synaptic activity-regulated gene, encodes a novel Ras-related protein. J. Biol. Chem. 269: 16333-16339.
76. Gromov, P. S., P. Madsen, N. Tomerup, and J. E. Celis. 1995. A novel approach for expression cloning of small GTPases: identification, tissue distribution and chromosome mapping of the human homolog of rheb. FEBS Lett. 377: 221-226.
77. Basso, A. D., A. Mirza, G. Liu, B. J. Long, W. R. Bishop, and P. Kirschmeier. 2005. The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen antitumor activity. J. Biol. Chem. 280: 31101-31108.
78. Tee, A. R., B. D. Manning, P. P. Roux, L. C. Cantley, and J. Blenis. 2003. Tuberous sclerosis complex gene products, tuberin and hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr. Biol. 13: 1259-1268.
79. Inoki, K., Y. Li, T. Xu, and K. L. Guan. 2003. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 17: 1829-1834.
80. Garami, A., F. J. Zwartkruis, T. Nobukuni, M. Joaquin, M. Roccio, H. Stocker, S. C. Kozma, E. Hafen, J. L. Bos, and G. Thomas. 2003. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol. Cell. 11: 1457-1466.
81. Zhang, Y., X. Gao, L. J. Saucedo, B. Ru, B. A. Edgar, and D. Pan. 2003. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat. Cell Biol. 5: 578-581.
82. The European Chromosome 16 Tuberous Sclerosis Consortium. 1993. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell. 75: 1305-1315.
83. van Slegtenhorst, M., R. de Hoogt, C. Hermans, M. Nellist, B. Janssen, S. Verhoef, D. Lindhout, A. van den Ouweland, D. Halley, J. Young, et al. 1997. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science. 277: 805-808.
84. Inoki, K., Y. Li, T. Zhu, J. Wu, and K. L. Guan. 2002. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 4: 648-657.
85. Li, Y., K. Inoki, R. Yeung, and K. L. Guan. 2002. Regulation of TSC2 by 14-3-3 binding. J. Biol. Chem. 277: 44593-44596.
86. Potter, C. J., L. G. Pedraza, and T. Xu. 2002. Akt regulates growth by directly phosphorylating Tsc2. Nat. Cell Biol. 4: 658-665.
87. Liu, M. Y., S. Cai, A. Espejo, M. T. Bedford, and C. L. Walker. 2002. 14-3-3 interacts with the tumor suppressor tuberin at Akt phosphorylation site(s). Cancer Res. 62: 6475-6480.
88. Manning, B. D., A. R. Tee, M. N. Logsdon, J. Blenis, and L. C. Cantley. 2002. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol. Cell. 10: 151-162.
89. Shaw, R. J., N. Bardeesy, B. D. Manning, L. Lopez, M. Kosmatka, R. A. DePinho, and L. C. Cantley. 2004. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell. 6: 91-99.
90. Inoki, K., T. Zhu, and K. L. Guan. 2003. TSC2 mediates cellular energy response to control cell growth and survival. Cell. 115: 577-590.
91. Jenne, D. E., H. Reimann, J. Nezu, W. Friedel, S. Loff, R. Jeschke, O. Muller, W. Back, and M. Zimmer. 1998. Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat. Genet. 18: 38-43.
92. Hemminki, A., D. Markie, I. Tomlinson, E. Avizienyte, S. Roth, A. Loukola, G. Bignell, W. Warren, M. Aminoff, P. Hoglund, et al. 1998. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature. 391: 184-187.
93. Castro, A. F., J. F. Rebhun, G. J. Clark, and L. A. Quilliam. 2003. Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner. J. Biol. Chem. 278: 32493-32496.
94. Tabancay, A. P., Jr., C. L. Gau, I. M. Machado, E. J. Uhlmann, D. H. Gutmann, L. Guo, and F. Tamanoi. 2003. Identification of dominant negative mutants of Rheb GTPase and their use to implicate the involvement of human Rheb in the activation of p70S6K. J. Biol. Chem. 278: 39921-39930.
95. Smith, E. M., S. G. Finn, A. R. Tee, G. J. Browne, and C. G. Proud. 2005. The tuberous sclerosis protein TSC2 is not required for the regulation of the mammalian target of rapamycin by amino acids and certain cellular stresses. J. Biol. Chem. 280: 18717-18727.
96. Long, X., Y. Lin, S. Ortiz-Vega, K. Yonezawa, and J. Avruch. 2005. Rheb binds and regulates the mTOR kinase. Curr Biol. 15: 702-713.
97. Patel, P. H., N. Thapar, L. Guo, M. Martinez, J. Maris, C. L. Gau, J. A. Lengyel, and F. Tamanoi. 2003. Drosophila Rheb GTPase is required for cell cycle progression and cell growth. J. Cell Sci. 116: 3601-3610.
98. Saucedo, L. J., X. Gao, D. A. Chiarelli, L. Li, D. Pan, and B. A. Edgar. 2003. Rheb promotes cell growth as a component of the insulin/TOR signalling network. Nat. Cell Biol. 5: 566-571.
99. Stocker, H., T. Radimerski, B. Schindelholz, F. Wittwer, P. Belawat, P. Daram, S. Breuer, G. Thomas, and E. Hafen. 2003. Rheb is an essential regulator of S6K in controlling cell growth in Drosophila. Nat. Cell Biol. 5: 559-565.
100. Gau, C. L., J. Kato-Stankiewicz, C. Jiang, S. Miyamoto, L. Guo, and F. Tamanoi. 2005. Farnesyltransferase inhibitors reverse altered growth and distribution of actin filaments in Tsc-deficient cells via inhibition of both rapamycin-sensitive and -insensitive pathways. Mol. Cancer Ther. 4: 918-926.
101. Yao, X., K. L. Anderson, and D. W. Cleveland. 1997. The microtubule-dependent motor centromere-associated protein E (CENP-E) is an integral component of kinetochore corona fibers that link centromeres to spindle microtubules. J. Cell Biol. 139: 435-447.
102. Wood, K. W., R. Sakowicz, L. S. Goldstein, and D. W. Cleveland. 1997. CENP-E is a plus end-directed kinetochore motor required for metaphase chromosome alignment. Cell. 91: 357-366.
103. Liao, H., R. J. Winkfein, G. Mack, J. B. Rattner, and T. J. Yen. 1995. CENP-F is a protein of the nuclear matrix that assembles onto kinetochores at late G2 and is rapidly degraded after mitosis. J. Cell Biol. 130: 507-518.
104. Crespo, N. C., J. Ohkanda, T. J. Yen, A. D. Hamilton, and S. M. Sebti. 2001. The farnesyltransferase inhibitor, FTI-2153, blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells. J. Biol. Chem. 276: 16161-16167.
105. Hussein, D., and S. S. Taylor. 2002. Farnesylation of Cenp-F is required for G2/M progression and degradation after mitosis. J. Cell Sci. 115: 3403-3414.
106. Cates, C. A., R. L. Michael, K. R. Stayrook, K. A. Harvey, Y. D. Burke, S. K. Randall, P. L. Crowell, and D. N. Crowell. 1996. Prenylation of oncogenic human PTP(CAAX) protein tyrosine phosphatases. Cancer Lett. 110: 49-55.
107. Zeng, Q., J. M. Dong, K. Guo, J. Li, H. X. Tan, V. Koh, C. J. Pallen, E. Manser, and W. Hong. 2003. PRL-3 and PRL-1 promote cell migration, invasion, and metastasis. Cancer Res. 63: 2716-2722.
108. Zeng, Q., X. Si, H. Horstmann, Y. Xu, W. Hong, and C. J. Pallen. 2000. Prenylation-dependent association of protein-tyrosine phosphatases PRL-1, -2, and -3 with the plasma membrane and the early endosome. J. Biol. Chem. 275: 21444-21452.
109. Nagata, H., W. J. Hansen, B. Freeman, and W. J. Welch. 1998. Mammalian cytosolic DnaJ homologues affect the hsp70 chaperone-substrate reaction cycle, but do not interact directly with nascent or newly synthesized proteins. Biochemistry. 37: 6924-6938.
110. Liberek, K., J. Marszalek, D. Ang, C. Georgopoulos, and M. Zylicz. 1991. Escherichia coli DnaJ and GrpE heat shock proteins jointly stimulate ATPase activity of DnaK. Proc. Natl. Acad. Sci. USA. 88: 2874-2878.
111. Caplan, A. J., D. M. Cyr, and M. G. Douglas. 1992. YDJ1p facilitates polypeptide translocation across different intracellular membranes by a conserved mechanism. Cell. 71: 1143-1155.
112. Terada, K., M. Kanazawa, B. Bukau, and M. Mori. 1997. The human DnaJ homologue dj2 facilitates mitochondrial protein import and luciferase refolding. J. Cell Biol. 139: 1089-1095.
113. Tang, Y., C. Ramakrishnan, J. Thomas, and D. B. DeFranco. 1997. A role for HDJ-2/HSDJ in correcting subnuclear trafficking, transactivation, and transrepression defects of a glucocorticoid receptor zinc finger mutant. Mol. Biol. Cell. 8: 795-809.
114. Fliss, A. E., J. Rao, M. W. Melville, M. E. Cheetham, and A. J. Caplan. 1999. Domain requirements of DnaJ-like (Hsp40) molecular chaperones in the activation of a steroid hormone receptor. J. Biol. Chem. 274: 34045-34052.
115. Aebi, U., J. Cohn, L. Buhle, and L. Gerace. 1986. The nuclear lamina is a meshwork of intermediate-type filaments. Nature. 323: 560-564.
116. Ulitzur, N., A. Harel, N. Feinstein, and Y. Gruenbaum. 1992. Lamin activity is essential for nuclear envelope assembly in a Drosophila embryo cell-free extract. J. Cell Biol. 119: 17-25.
117. Beck, L. A., T. J. Hosick, and M. Sinensky. 1990. Isoprenylation is required for the processing of the lamin A precursor. J. Cell Biol. 110: 1489-1499.
118. Weber, K., U. Plessmann, and P. Traub. 1989. Maturation of nuclear lamin A involves a specific carboxy-terminal trimming, which removes the polyisoprenylation site from the precursor: implications for the structure of the nuclear lamina. FEBS Lett. 257: 411-414.
119. Corrigan, D. P., D. Kuszczak, A. E. Rusinol, D. P. Thewke, C. A. Hrycyna, S. Michaelis, and M. S. Sinensky. 2005. Prelamin A endoproteolytic processing in vitro by recombinant Zmpste24. Biochem. J. 387: 129-138.
120. Sinensky, M., K. Fantle, and M. Dalton. 1994. An antibody which specifically recognizes prelamin A but not mature lamin A: application to detection of blocks in farnesylation-dependent protein processing. Cancer Res. 54: 3229-3232.
121. Adjei, A. A., C. Erlichman, J. N. Davis, D. L. Cutler, J. A. Sloan, R. S. Marks, L. J. Hanson, P. A. Svingen, P. Atherton, W. R. Bishop, et al. 2000. Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. Cancer Res. 60: 1871-1877.
122. Adjei, A. A., J. N. Davis, C. Erlichman, P. A. Svingen, and S. H. Kaufmann. 2000. Comparison of potential markers of farnesyltransferase inhibition. Clin. Cancer Res. 6: 2318-2325.
123. Lutz, R. J., M. A. Trujillo, K. S. Denham, L. Wenger, and M. Sinensky. 1992. Nucleoplasmic localization of prelamin A: implications for prenylation-dependent lamin A assembly into the nuclear lamina. Proc. Natl. Acad. Sci. USA. 89: 3000-3004.
124. Sasseville, A. M., and Y. Raymond. 1995. Lamin A precursor is localized to intranuclear foci. J. Cell Sci. 108: 273-285.
125. Hennekes, H., and E. A. Nigg. 1994. The role of isoprenylation in membrane attachment of nuclear lamins. A single point mutation prevents proteolytic cleavage of the lamin A precursor and confers membrane binding properties. J. Cell Sci. 107: 1019-1029.
126. Barton, R. M., and H. J. Worman. 1999. Prenylated prelamin A interacts with Narf, a novel nuclear protein. J. Biol. Chem. 274: 30008-30018.
127. De Sandre-Giovannoli, A., R. Bernard, P. Cau, C. Navarro, J. Amiel, I. Boccaccio, S. Lyonnet, C. L. Stewart, A. Munnich, M. Le Merrer, et al. 2003. Lamin A truncation in Hutchinson-Gilford progeria. Science. 300: 2055.
128. Eriksson, M., W. T. Brown, L. B. Gordon, M. W. Glynn, J. Singer, L. Scott, M. R. Erdos, C. M. Robbins, T. Y. Moses, P. Berglund, et al. 2003. Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature. 423: 293-298.
129. Goldman, R. D., D. K. Shumaker, M. R. Erdos, M. Eriksson, A. E. Goldman, L. B. Gordon, Y. Gruenbaum, S. Khuon, M. Mendez, R. Varga, et al. 2004. Accumulation of mutant lamin A causes progressive changes in nuclear architecture in Hutchinson-Gilford progeria syndrome. Proc. Natl. Acad. Sci. USA. 101: 8963-8968.
130. Bergo, M. O., B. Gavino, J. Ross, W. K. Schmidt, C. Hong, L. V. Kendall, A. Mohr, M. Meta, H. Genant, Y. Jiang, et al. 2002. Zmpste24 deficiency in mice causes spontaneous bone fractures, muscle weakness, and a prelamin A processing defect. Proc. Natl. Acad. Sci. USA. 99: 13049-13054.
131. Navarro, C. L., J. Cadinanos, A. De Sandre-Giovannoli, R. Bernard, S. Courrier, I. Boccaccio, A. Boyer, W. J. Kleijer, A. Wagner, F. Giuliano, et al. 2005. Loss of ZMPSTE24 (FACE-1) causes autosomal recessive restrictive dermopathy and accumulation of lamin A precursors. Hum. Mol. Genet. 14: 1503-1513.
132. Yang, S. H., M. O. Bergo, J. I. Toth, X. Qiao, Y. Hu, S. Sandoval, M. Meta, P. Bendale, M. H. Gelb, S. G. Young, et al. 2005. Blocking protein farnesyltransferase improves nuclear blebbing in mouse fibroblasts with a targeted Hutchinson-Gilford progeria syndrome mutation. Proc. Natl. Acad. Sci. USA. 102: 10291-10296.
133. Toth, J. I., S. H. Yang, X. Qiao, A. P. Beigneux, M. H. Gelb, C. L. Moulson, J. H. Miner, S. G. Young, and L. G. Fong. 2005. Blocking protein farnesyltransferase improves nuclear shape in fibroblasts from humans with progeroid syndromes. Proc. Natl. Acad. Sci. USA. 102: 12873-12878.
134. Capell, B. C., M. R. Erdos, J. P. Madigan, J. J. Fiordalisi, R. Varga, K. N. Conneely, L. B. Gordon, C. J. Der, A. D. Cox, and F. S. Collins. 2005. Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome. Proc. Natl. Acad. Sci. USA. 102: 12879-12884.
135. Elam, C., L. Hesson, M. D. Vos, K. Eckfeld, C. A. Ellis, A. Bell, D. Krex, M. J. Birrer, F. Latif, and G. J. Clark. 2005. RRP22 is a farnesylated, nucleolar, Ras-related protein with tumor suppressor potential. Cancer Res. 65: 3117-3125.
136. O'Meara, S. J., and B. T. Kinsella. 2004. Investigation of the effect of the farnesyl protein transferase inhibitor R115777 on isoprenylation and intracellular signalling by the prostacyclin receptor. Br. J. Pharmacol. 143: 318-330.
137. Liu, M., M. S. Bryant, J. Chen, S. Lee, B. Yaremko, P. Lipari, M. Malkowski, E. Ferrari, L. Nielsen, N. Prioli, et al. 1998. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. Cancer Res. 58: 4947-4956.
138. Ashar, H. R., L. James, K. Gray, D. Carr, M. McGuirk, E. Maxwell, S. Black, L. Armstrong, R. J. Doll, A. G. Taveras, et al. 2001. The farnesyl transferase inhibitor SCH 66336 induces a G(2) → M or G(1) pause in sensitive human tumor cell lines. Exp. Cell Res. 262: 17-27.
139. Suzuki, N., J. Urano, and F. Tamanoi. 1998. Farnesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cells. Proc. Natl. Acad. Sci. USA. 95: 15356-15361.
140. Lebowitz, P. F., D. Sakamuro, and G. C. Prendergast. 1997. Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment. Cancer Res. 57: 708-713.
141. Brassard, D. L., J. M. English, M. Malkowski, P. Kirschmeier, T. L. Nagabhushan, and W. R. Bishop. 2002. Inhibitors of farnesyl protein transferase and MEK1,2 induce apoptosis in fibroblasts transformed with farnesylated but not geranylgeranylated H-Ras. Exp. Cell Res. 273: 138-146.
142. Tamanoi, F., J. Kato-Stankiewicz, C. Jiang, I. Machado, and N. Thapar. 2001. Farnesylated proteins and cell cycle progression. J. Cell. Biochem. Suppl. 37: 64-70.
143. Sepp-Lorenzino, L., Z. Ma, E. Rands, N. E. Kohl, J. B. Gibbs, A. Oliff, and N. Rosen. 1995. A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res. 55: 5302-5309.
144. Yan, N., C. Ricca, J. Fletcher, T. Glover, B. R. Seizinger, and V. Manne. 1995. Farnesyltransferase inhibitors block the neurofibromatosis type I (NF1) malignant phenotype. Cancer Res. 55: 3569-3575.
145. Norgaard, P., B. Law, H. Joseph, D. L. Page, Y. Shyr, D. Mays, J. A. Pietenpol, N. E. Kohl, A. Oliff, R. J. Coffey, Jr., et al. 1999. Treatment with
146. Feldkamp, M. M., P. Lala, N. Lau, L. Roncari, and A. Guha. 1999. Expression of activated epidermal growth factor receptors, Rasguanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens. Neurosurgery. 45: 1442-1453.
147. Feldkamp, M. M., N. Lau, L. Roncari, and A. Guha. 2001. Isotypespecific Ras.GTP-levels predict the efficacy of farnesyl transferase inhibitors against human astrocytomas regardless of Ras mutational status. Cancer Res. 61: 4425-4431.
148. Sepp-Lorenzino, L., and N. Rosen. 1998. A farnesyl-protein transferase inhibitor induces p21 expression and G1 block in p53 wild type tumor cells. J. Biol. Chem. 273: 20243-20251.
149. Sun, J., Y. Qian, A. D. Hamilton, and S. M. Sebti. 1995. Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion. Cancer Res. 55: 4243-4247.
150. Rose, W. C., F. Y. Lee, C. R. Fairchild, M. Lynch, T. Monticello, R. A. Kramer, and V. Manne. 2001. Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyltransferase inhibitor. Cancer Res. 61: 7507-7517.
151. Peters, D. G., R. R. Hoover, M. J. Gerlach, E. Y. Koh, H. Zhang, K. Choe, P. Kirschmeier, W. R. Bishop, and G. Q. Daley. 2001. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia. Blood. 97: 1404-1412.
152. Reichert, A., N. Heisterkamp, G. Q. Daley, and J. Groffen. 2001. Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336. Blood. 97: 1399-1403.
153. Mishra, S., B. Zhang, J. Groffen, and N. Heisterkamp. 2004. A farnesyltransferase inhibitor increases survival of mice with very advanced stage acute lymphoblastic leukemia/lymphoma caused by P190 Bcr/Abl. Leukemia. 18: 23-28.
154. Hoover, R. R., F. X. Mahon, J. V. Melo, and G. Q. Daley. 2002. Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood. 100: 1068-1071.
155. Nakajima, A., T. Tauchi, M. Sumi, W. R. Bishop, and K. Ohyashiki. 2003. Efficacy of SCH66336, a farnesyl transferase inhibitor, in conjunction with imatinib against BCR-ABL-positive cells. Mol. Cancer Ther. 2: 219-224.
156. Jiang, K., D. Coppola, N. C. Crespo, S. V. Nicosia, A. D. Hamilton, S. M. Sebti, and J. Q. Cheng. 2000. The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. Mol. Cell. Biol. 20: 139-148.
157. Chun, K. H., H. Y. Lee, K. Hassan, F. Khuri, W. K. Hong, and R. Lotan. 2003. Implication of protein kinase B/Akt and Bcl-2/ Bcl-XL suppression by the farnesyl transferase inhibitor SCH66336 in apoptosis induction in squamous carcinoma cells. Cancer Res. 63: 4796-4800.
158. Sun, S. Y., Z. Zhou, R. Wang, H. Fu, and F. R. Khuri. 2004. The farnesyltransferase inhibitor lonafarnib induces growth arrest or apoptosis of human lung cancer cells without downregulation of akt. Cancer Biol. Ther. 3: 1092-1098.
159. Beaupre, D. M., J. McCafferty-Grad, N. J. Bahlis, L. H. Boise, and M. G. Lichtenheld. 2003. Farnesyl transferase inhibitors enhance death receptor signals and induce apoptosis in multiple myeloma cells. Leuk. Lymphoma. 44: 2123-2134.
160. Feldkamp, M. M., N. Lau, and A. Guha. 1998. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and antiangiogenic effects. Oncogene. 18: 7514-7526.
161. Marzo, I., P. Perez-Galan, P. Giraldo, N. Lopez-Royuela, M. Gomez-Benito, L. Larrad, P. Lasierra, D. Rubio-Felix, A. Anel, and J. Naval. 2004. Farnesyltransferase inhibitor BMS-214662 induces apoptosis in B-cell chronic lymphocytic leukemia cells. Leukemia. 18: 1599-1604.
162. Pan, J., M. She, Z. X. Xu, L. Sun, and S. C. Yeung. 2005. Farnesyltransferase inhibitors induce DNA damage via reactive oxygen species in human cancer cells. Cancer Res. 65: 3671-3681.
163. Moasser, M. M., L. Sepp-Lorenzino, N. E. Kohl, A. Oliff, A. Balog, D. S. Su, S. J. Danishefsky, and N. Rosen. 1998. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc. Natl. Acad. Sci. USA. 95: 1369-1374.
164. Adjei, A. A., J. N. Davis, L. M. Bruzek, C. Erlichman, and S. H. Kaufmann. 2001. Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines. Clin. Cancer Res. 7: 1438-1445.
165. Doisneau-Sixou, S. F., P. Cestac, J. C. Faye, G. Favre, and R. L. Sutherland. 2003. Additive effects of tamoxifen and the farnesyl transferase inhibitor FTI-277 on inhibition of MCF-7 breast cancer cell-cycle progression. Int. J. Cancer. 106: 789-798.
166. Edamatsu, H., C. L. Gau, T. Nemoto, L. Guo, and F. Tamanoi. 2000. Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines. Oncogene. 19: 3059-3068.
167. Russo, P., D. Malacarne, C. Falugi, S. Trombino, and P. M. O'Connor. 2002. RPR-115135, a farnesyltransferase inhibitor, increases 5-FU cytotoxicity in ten human colon cancer cell lines: role of p53. Int. J. Cancer. 100: 266-275.
168. Shi, B., B. Yaremko, G. Hajian, G. Terracina, W. R. Bishop, M. Liu, and L. L. Nielsen. 2000. The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo. Cancer Chemother. Pharmacol. 46: 387-393.
169. Delmas, C., C. Heliez, E. Cohen-Jonathan, D. End, J. Bonnet, G. Favre, and C. Toulas. 2002. Farnesyltransferase inhibitor, R115777, reverses the resistance of human glioma cell lines to ionizing radiation. Int. J. Cancer. 100: 43-48.
170. Brunner, T. B., A. K. Gupta, Y. Shi, S. M. Hahn, R. J. Muschel, W. G. McKenna, and E. J. Bernhard. 2003. Farnesyltransferase inhibitors as radiation sensitizers. Int. J. Radiat. Biol. 79: 569-576.
171. Jorgensen, H. G., E. K. Allan, S. M. Graham, J. L. Godden, L. Richmond, M. A. Elliott, J. C. Mountford, C. J. Eaves, and T. L. Holyoake. 2005. Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro. Leukemia. 19: 1184-1191.
172. Zhu, K., E. Gerbino, D. M. Beaupre, P. A. Mackley, C. Muro-Cacho, C. Beam, A. D. Hamilton, M. G. Lichtenheld, W. G. Kerr, W. Dalton, et al. 2005. Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells. Blood. 105: 4759-4766.
173. Marcus, A. I., J. Zhou, A. O'Brate, E. Hamel, J. Wong, M. Nivens, A. El-Naggar, T. P. Yao, F. R. Khuri, and P. Giannakakou. 2005. The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase. Cancer Res. 65: 3883-3893.
174. Awada, A., F. A. Eskens, M. Piccart, D. L. Cutler, A. van der Gaast, H. Bleiberg, J. Wanders, M. N. Faber, P. Statkevich, P. Fumoleau, et al. 2002. Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours. Eur. J. Cancer. 38: 2272-2278.
175. Eskens, F. A., A. Awada, D. L. Cutler, M. J. de Jonge, G. P. Luyten, M. N. Faber, P. Statkevich, A. Sparreboom, J. Verweij, A. R. Hanauske, et al. 2001. Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors. J. Clin. Oncol. 19: 1167-1175.
176. Khuri, F. R., B. S. Glisson, E. S. Kim, P. Statkevich, P. F. Thall, M. L. Meyers, R. S. Herbst, R. F. Munden, C. Tendler, Y. Zhu, et al. 2002. Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors. Clin. Cancer Res. 10: 2968-2976.
177. Kim, E. S., M. S. Kies, F. V. Fossella, B. S. Glisson, S. Zaknoen, P. Statkevich, R. F. Munden, C. Summey, K. M. Pisters, V. Papadimitrakopoulou, et al. 2005. Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma. Cancer. 104: 561-569.
178. Rossner, D., B. Hollwitz, C. Schaff, A. Ay, F. Rinnau, W. Lersch, and H. Kühnle. 2004. The combination of paclitaxel and the farnesyltransferase inhibitor SCH 66336 in the treatment of metastatic breast cancer. A phase I/II study (Abstract 1068 in San Antonio Breast Cancer Symposium Annual Meeting, San Antonio, TX, December 8-11, 2004).
179. Sharma, S., N. Kemeny, D. P. Kelsen, D. Ilson, E. O'Reilly, S. Zaknoen, C. Baum, P. Statkevich, E. Hollywood, Y. Zhu, et al. 2002. A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan. Ann. Oncol. 13: 1067-1071.
180. Winquist, E., M. J. Moore, K. N. Chi, D. S. Ernst, H. Hirte, S. North, J. Powers, W. Walsh, T. Boucher, R. Patton, et al. 2002. A multinomial phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer. Urol. Oncol. 23: 143-149.
181. Kieran, M. W., R. Packer, J. Boyett, M. Sugrue, and L. Kun. 2004. Phase I trial of the oral farnesyl protein transferase inhibitor lonafarnib (SCH66336): a Pediatric Brain Tumor Consortium (PBTC) study (Abstract 1517 in American Society of Clinical Oncology Annual Meeting , New Orleans, LA, June 5-8, 2004).
182. List, A., D. DeAngelo, S. O'Brien, J. Cortes, J. Wilson, M. Sugrue, Y. Zhu, P. Statkevich, C. Baum, and S. Zaknoen. 2002. Phase I study of continuous oral administration of lonafarnib (Sarasar™) in patients with advanced hematologic malignancies (Abstract 3120 in American Society of Hematology Annual Meeting, Philadelphia, PA, December 6-10, 2002).
183. Feldman, E., J. Cortes, T. Holyoake, S. Simonsson, D. De Angelo, J. Lipton, A. Turner, M. Baccarani, J. Barker, F. Guilhot, et al. 2003. Continuous oral lonafarnib (Sarasar) for the treatment of patients with myelodysplastic syndrome (Abstract 1531 in American Society of Hematology Annual Meeting, San Diego, CA, December 6-9, 2003).
184. Buresh, A., J. Perentesis, L. Rimsza, S. Kurtin, R. Heaton, M. Sugrue, and A. List. 2005. Hyperleukocytosis complicating lonafarnib treatment in patients with chronic myelomonocytic leukemia. Leukemia. 19: 308-310.
185. Cortes, J., S. O'Brien, V. Verstovsek, G. Daley, C. Koller, A. Ferrajoli, O. Pate, S. Faderl, F. Ravandi-Kashani, M. Talpaz, et al. 2004. Phase I study of lonafarnib (SCH66336) in combination with imatinib for patients (Pts) with chronic myeloid leukemia (CML) after failure to imatinib (Abstract 1009 in American Society of Hematology Annual Meeting, San Diego, CA, December 4-7, 2004).
186. Jabbour, E., H. Kantarjian, and J. Cortes. 2004. Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action. Leuk. Lymphoma. 45: 2187-2195.
187. Zujewski, J., I. D. Horak, C. J. Bol, R. Woestenborghs, C. Bowden, D. W. End, V. K. Piotrovsky, J. Chiao, R. T. Belly, A. Todd, et al. 2000. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J. Clin. Oncol. 18: 927-941.
188. Punt, C. J., L. van Maanen, C. J. Bol, W. F. Seifert, and D. J. Wagener. 2001. Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors. Anticancer Drugs. 12: 193-197.
189. Crul, M., G. J. de Klerk, M. Swart, L. J. van't Veer, D. de Jong, L. Boerrigter, P. A. Palmer, C. J. Bol, H. Tan, G. C. de Gast, et al. 2002. Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer. J. Clin. Oncol. 20: 2726-2735.
190. Karp, J. E., J. E. Lancet, S. H. Kaufmann, D. W. End, J. J. Wright, K. Bol, I. Horak, M. L. Tidwell, J. Liesveld, T. J. Kottke, et al. 2001. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood. 97: 3361-3369.
191. Zimmerman, T. M., H. Harlin, O. M. Odenike, S. Berk, E. Sprague, T. Karrison, W. Stock, R. A. Larson, M. J. Ratain, and T. F. Gajewski. 2004. Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies. J. Clin. Oncol. 22: 4816-4822.
192. Kurzrock, R., H. M. Kantarjian, J. E. Cortes, N. Singhania, D. A. Thomas, E. F. Wilson, J. J. Wright, E. J. Freireich, M. Talpaz, and S. M. Sebti. 2003. Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. Blood. 102: 4527-4534.
193. Kurzrock, R., M. Albitar, J. E. Cortes, E. H. Estey, S. H. Faderl, G. Garcia-Manero, D. A. Thomas, F. J. Giles, M. E. Ryback, A. Thibault, et al. 2004. Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. J. Clin. Oncol. 22: 1287-1292.
194. Cortes, J., M. Albitar, D. Thomas, F. Giles, R. Kurzrock, A. Thibault, W. Rackoff, C. Koller, S. O'Brien, G. Garcia-Manero, et al. 2003. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood. 101: 1692-1697.
195. Alsina, M., R. Fonseca, E. F. Wilson, A. N. Belle, E. Gerbino, T. Price-Troska, R. M. Overton, G. Ahmann, L. M. Bruzek, A. A. Adjei, et al. 2004. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood. 103: 3271-3277.
196. Lara, P. N., Jr., L. Y. Law, J. J. Wright, P. Frankel, P. Twardowski, H. J. Lenz, D. H. Lau, T. Kawaguchi, P. H. Gumerlock, J. H. Doroshow, et al. 2005. Intermittent dosing of the farnesyl transferase inhibitor tipifarnib (R115777) in advanced malignant solid tumors: a phase I California Cancer Consortium trial. Anticancer Drugs. 16: 317-321.
197. Gotlib, J. 2005. Farnesyltransferase inhibitor therapy in acute myelogenous leukemia. Curr. Hematol. Rep. 4: 77-84.
198. Heymach, J. V., D. H. Johnson, F. R. Khuri, H. Safran, L. L. Schlabach, F. Yunus, R. F. DeVore 3rd, P. M. De Porre, H. M. Richards, X. Jia, et al. 2004. Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer. Ann. Oncol. 15: 1187-1193.
199. Adjei, A. A., A. Mauer, L. Bruzek, R. S. Marks, S. Hillman, S. Geyer, L. J. Hanson, J. J. Wright, C. Erlichman, S. H. Kaufmann, et al. 2003. Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 21: 1760-1766.
200. Cohen, S. J., L. Ho, S. Ranganathan, J. L. Abbruzzese, R. K. Alpaugh, M. Beard, N. L. Lewis, S. McLaughlin, A. Rogatko, J. J. Perez-Ruixo, et al. 2003. Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J. Clin. Oncol. 21: 1301-1306.
201. Rao, S., D. Cunningham, A. de Gramont, W. Scheithauer, M. Smakal, Y. Humblet, G. Kourteva, T. Iveson, T. Andre, J. Dostalova, et al. 2004. Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. J. Clin. Oncol. 22: 3950-3957.
202. Rosenberg, J. E., H. von der Maase, J. D. Seigne, J. Mardiak, D. J. Vaughn, M. Moore, D. Sahasrabudhe, P. A. Palmer, J. J. Perez-Ruixo, and E. J. Small. 2005. A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma. Cancer. 103: 2035-2041.
203. Johnston, S. R., T. Hickish, P. Ellis, S. Houston, L. Kelland, M. Dowsett, J. Salter, B. Michiels, J. J. Perez-Ruixo, P. Palmer, et al. 2003. Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. J. Clin. Oncol. 21: 2492-2499.
204. Sparreboom, A., D. F. Kehrer, R. H. Mathijssen, R. Xie, M. J. de Jonge, P. de Bruijn, A. S. Planting, F. A. Eskens, C. Verheij, G. de Heus, et al. 2004. Phase I and pharmacokinetic study of irinotecan in combination with R115777, a farnesyl protein transferase inhibitor. Br. J. Cancer. 90: 1508-1515.
205. Patnaik, A., S. G. Eckhardt, E. Izbicka, A. A. Tolcher, L. A. Hammond, C. H. Takimoto, G. Schwartz, H. McCreery, A. Goetz, M. Mori, et al. 2003. A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignancies. Clin. Cancer Res. 9: 4761-4771.
206. Adjei, A. A., G. A. Croghan, C. Erlichman, R. S. Marks, J. M. Reid, J. A. Sloan, H. C. Pitot, S. R. Alberts, R. M. Goldberg, L. J. Hanson, et al. 2003. Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer. Clin. Cancer Res. 9: 2520-2526.
207. Van Cutsem, E., H. van de Velde, P. Karasek, H. Oettle, W. L. Vervenne, A. Szawlowski, P. Schoffski, S. Post, C. Verslype, H. Neumann, et al. 2004. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J. Clin. Oncol. 22: 1430-1438.
208. Lebowitz, P. F., J. Eng-Wong, B. C. Widemann, F. M. Balis, N. Jayaprakash, C. Chow, G. Clark, S. B. Gantz, D. Venzon, and J. Zujewski. 2005. A phase I trial and pharmacokinetic study of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in metastatic breast cancer. Clin. Cancer Res. 11: 1247-1252.
209. Head, J., and S. R. Johnston. 2004. New targets for therapy in breast cancer: farnesyltransferase inhibitors. Breast Cancer Res. 6: 262-268.
210. Ryan, D. P., J. P. Eder, Jr., T. Puchlaski, M. V. Seiden, T. J. Lynch, C. S. Fuchs, P. C. Amrein, D. Sonnichsen, J. G. Supko, and J. W. Clark. 2004. Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 given as a 1-hour intravenous infusion in patients with advanced solid tumors. Clin. Cancer Res. 10: 2222-2230.
211. Mackay, H. J., R. Hoekstra, F. A. Eskens, W. J. Loos, D. Crawford, M. Voi, A. Van Vreckem, T. R. Evans, and J. Verweij. 2004. A phase I pharmacokinetic and pharmacodynamic study of the farnesyl transferase inhibitor BMS-214662 in combination with cisplatin in patients with advanced solid tumors. Clin. Cancer Res. 10: 2636-2644.
212. Dy, G. K., L. M. Bruzek, G. A. Croghan, S. Mandrekar, C. Erlichman, P. Peethambaram, H. C. Pitot, L. J. Hanson, J. M. Reid, A. Furth, et al. 2005. A phase I trial of the novel farnesyl protein transferase inhibitor, BMS-214662, in combination with paclitaxel and carboplatin in patients with advanced cancer. Clin. Cancer Res. 11: 1877-1883.
213. Cortes, J., S. Faderl, E. Estey, R. Kurzrock, D. Thomas, M. Beran, G. Garcia-Manero, A. Ferrajoli, F. Giles, C. Koller, et al. 2005. Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes. J. Clin. Oncol. 23: 2805-2812.
214. Papadimitrakopoulou, V., S. Agelaki, H. T. Tran, M. Kies, R. Gagel, R. Zinner, E. Kim, G. Ayers, J. Wright, and F. Khuri. 2005. Phase I study of the farnesyltransferase inhibitor BMS-214662 given weekly in patients with solid tumors. Clin. Cancer Res. 11: 4151-4159.
215. Tabernero, J., F. Rojo, I. Marimon, M. Voi, J. Albanell, M. Guix, F. Vazquez, J. Carulla, M. Cooper, J. Andreu, et al. 2005. Phase I pharmacokinetic and pharmacodynamic study of weekly 1-hour and 24-hour infusion BMS-214662, a farnesyltransferase inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 23: 2521-2533.
216. Britten, C. D., E. K. Rowinsky, S. Soignet, A. Patnaik, S. L. Yao, P. Deutsch, Y. Lee, R. B. Lobell, K. E. Mazina, H. McCreery, et al. 2001. A phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778,123 in patients with solid malignancies. Clin. Cancer Res. 7: 3894-3903.
217. Martin, N. E., T. B. Brunner, K. D. Kiel, T. F. DeLaney, W. F. Regine, M. Mohiuddin, E. F. Rosato, D. G. Haller, J. P. Stevenson, D. Smith, et al. 2004. A phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancer. Clin. Cancer Res. 10: 5447-5454.
218. Hahn, S. M., E. J. Bernhard, W. Regine, M. Mohiuddin, D. G. Haller, J. P. Stevenson, D. Smith, B. Pramanik, J. Tepper, T. F. DeLaney, et al. 2002. Phase I trial of the farnesyltransferase inhibitor L-778,123 and radiotherapy for locally advanced lung and head and neck cancer. Clin. Cancer Res. 8: 1065-1072.
219. Lobell, R. B., D. Liu, C. A. Buser, J. P. Davide, E. DePuy, K. Hamilton, K. S. Koblan, Y. Lee, S. Mosser, S. L. Motzel, et al. 2002. Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-I. Mol. Cancer Ther. 1: 747-758.
220. Raponi, M., R. T. Belly, J. E. Karp, J. E. Lancet, D. Atkins, and Y. Wang. 2004. Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia. BMC Cancer. 4: 56-68.